Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease.

ABSTRACT: The conversion of cellular prion protein (PrP^C) into pathogenic prion isoforms (PrP^Sc) and the mutation of PRNP are definite causes of prion diseases. Unfortunately, without exception, prion diseases are untreatable and fatal neurodegenerative disorders; therefore, one area of research focuses on identifying medicines that can delay the progression of these diseases. According to the concept of drug repositioning, we investigated the efficacy of the c-Abl tyrosine kinase inhibitor radotinib, which is a drug that is approved for the treatment of chronic myeloid leukemia, in the treatment of disease progression in prion models, including prion-infected cell models, Tga20 and hamster cerebellar slice culture models, and 263K scrapie-infected hamster models.

SUBMITTER: Choi YG 

PROVIDER: S-EPMC10419185 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature